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http://www.biomedcentral.com/1471-2474/14/79RESEARCH ARTICLE Open AccessEvaluation of hand bone loss by digital X-ray
radiogrammetry as a complement to clinical and
radiographic assessment in early rheumatoid
arthritis: results from the SWEFOT trial
Hamed Rezaei1,2*, Saedis Saevarsdottir2, Pierre Geborek3, Ingemar F Petersson4, Ronald F van Vollenhoven1,2
and Kristina Forslind3,5Abstract
Background: To investigate hand bone loss (HBL) measured by digital X-ray radiogrammetry (DXR) in patients with
early rheumatoid arthritis (RA) receiving different treatment regimens, and to evaluate if DXR change rates during
the first 12 months correlate with radiological damage after 24 months.
Methods: From the total SWEFOT trial population, 159 patients had hand radiographs correctly timed and taken
with same modality to be analyzed with DXR. All patients started treatment with methotrexate. After 3–4 months,
patients with DAS28 > 3.2 were randomized to add sulfasalazine and hydroxychloroquine (triple therapy) or
infliximab (MTX + INF). Those with DAS28 ≤3.2 were followed in regular care. Radiographic progression over
24 months was scored according to the Sharp van der Heijde score (SHS) and defined as >5 increase in T-SHS over
24 months. Hand bone mineral density (BMD) was measured by DXR at inclusion and 12 months and a change
≥2.5 mg/cm2/month was used as a cut-off for HBL.
Results: In the MTX responders, triple therapy, and MTX + INF groups, the proportions with HBL were 4.1%, 22.2%
and 16.4%, respectively (p = 0.01), and the mean (SD) radiological progression in these groups was 3.91 (6.72), 7.40
(14.63) and 2.72 (4.55) respectively (p = 0.06). Patients with HBL had significantly greater risk for radiographic
progression, compared with patients without HBL (odds ratio 3.09, 95% CI =1.20–7.79, p = 0.02).
Conclusions: Non-responders to MTX had a significantly greater risk of HBL than MTX-responders, despite the
add-on therapies. Patients with HBL during the 12 months had greater risk of radiographic progression after
24 months. Evaluation of HBL may help to identify patients who are at risk of radiographic progression.Background
Chronic synovitis in rheumatoid arthritis (RA) can lead
to irreversible joint damage, which is seen on conven-
tional plain radiography [1]. Measurement of the degree
of joint damage represents an important tool to assess
disease progression and effectiveness of current treat-
ments [2,3]. Periarticular osteopenia, erosions and joint
space narrowing are radiographic features of RA that* Correspondence: hamed.rezaei@karolinska.se
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reproduction in any medium, provided the orcan be seen on conventional radiography of the hands
and feet [3,4]. Of these, periarticular osteopenia, reflec-
ting a reduction in bone mineral density (BMD), is one
of the earliest manifestations, and may precede erosion
and joint space narrowing [4]; it may be caused by local
release of inflammatory mediators and immobility [5,6].
The sensitivity of conventional radiography regarding
osteopenia is limited, as it can only be detected if the
reduction of bone density is more than 35–50% [7,8]. In
recent years, studies have been presented on an alternative
method for ascertaining inflammation-related osteopenia
in patients with RA, measuring BMD in the diaphyses of
the 2nd, 3rd and 4th metacarpal bone on conventionalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(DXR) [5,9-13]. DXR is a computerized version of the
earlier technique of radiogrammetry, measuring cortical
bone thickness as originally proposed by Barnett and
Nordin [14]. Prior studies have suggested that this new
technique has predictive value for RA-related joint dam-
ages and radiological progression [7,9,12,13,15]. Here, we
present data on hand BMD change measured by DXR
based on part of the SWEFOT (SWEdish PharmacOTher-
apy) early RA trial population [16].
The aim of this study was to determine whether hand
bone loss (HBL) analysed with DXR correlated with
radiographic progression, as measured by van der Heijde
modified Sharp score (SHS) [17] in patients with early
RA and to compare HBL and radiographic progression
in the three treatment groups of this trial.
Methods
Patients
This study consisted of 159 of the 487 patients with early
RA who participated in the SWEFOT trial and had
correctly timed hand radiographs with sufficient quality to
be analyzed with DXR. The SWEFOT trial was a collabo-
ration of 15 rheumatology units in Sweden between 2002
and 2008. At inclusion (baseline), all patients started treat-
ment with methotrexate (MTX) at a dose of 10 mg weekly,
which was escalated every 2 weeks by 5 mg up to 20 mg
weekly as target dose. All patients received folic acid
supplements and their liver enzymes and blood count tests
were monitored according to the local guidelines, with
dose adjustments if needed, as previously described [16].
After 3–4 months, patients with disease activity score
based on 28 joints count (DAS28) >3.2 were randomized
in two arms; combination of methotrexate and infliximab
[MTX+ INF] or MTX, sulfasalazine (SSZ) and hydroxy-
chloroquine (HCQ) [triple therapy]. A total of 147 pa-
tients reached low disease activity score (DAS28 ≤3.2)
[MTX monotherapy] and were not randomized in the trial
but were followed up in regular care as previously
described [16,18].
The study was approved by regional ethics committees
of all participating units [Karolinska Institute 02-211,
Örebro 2002/202 500:16, Umeå 2002, Linköping 02-186,
Uppsala Ups 02-241, Göteborg Gbg Ö 282-01, M 088-02,
Lund: LU 398-01 and Stockholm Central Ethical Review
Board (EPN)2005/1361, 2006/248-3]. All patients received
oral and written information prior to inclusion, and
consented to participate by signing the informed-consent
document. The patients were followed for 24 months.
Clinical assessment and physical functional
The disease activity was measured by DAS28 based on
erythrocyte sedimentation rate (ESR) [19]. ESR was
replaced by C-reactive protein (CRP) where ESR wasmissing [20]. Analysis of anti-citrullinated protein anti-
bodies (ACPA) was made with the standard Enzyme-
linked Immunosorbent assay (Immunoscan-RA Mark2
ELISA test, Euro-Diagnostica, Malmö, Sweden). Rheuma-
toid factor (RF) was measured by standard laboratory
methods at the participating clinics. The functional
disability was evaluated using the Swedish version of the
Stanford Health Assessment Questionnaire disability
index (HAQ) [21].
Radiographic assessment and digital X-ray
radiogrammetry (DXR)
Radiographs of hands and feet were performed at base-
line, after 12 and 24 months. The radiographic damage
was assessed in 144 of 159 patients according to the van
der Heijde modified Sharp score (SHS) allowing presen-
tation of total score [T-SHS (range 0–448)], erosion
score [ES (range 0–280)] and joint space narrowing
score [JSNS (range 0–168)] separately [22]. One of two
certified readers (KA, KF) who were blinded for the
treatment assignment read each set of radiographs in
chronological order. The inter-class correlation coeffi-
cient between the readers was 0.94 and smallest detect-
able change (SDC) was 5.8, calculated by the formula
described by Bruynesteyn et al. [23]. Radiographic pro-
gression was defined as an increase in T-SHS > 5 units
after 24 months [24].
Bone mineral density (BMD) of the hands was mea-
sured on hand radiographs in the 159 patients using
DXR (the online Pronosco X-posure System, SECTRA),
a computerized version of the traditional technique of
radiogrammetry measuring cortical bone thickness as
originally proposed by Barnett and Nordin [14]. With
this method, the narrowest part of the second, third and
forth metacarpal bones are identified. In each area, the
thickness and porosity of bone cortex are analyzed
around the centre and mid-shaft of the metacarpal bone
[25]. DXR of both hands were analyzed and the mean of
DXR-BMD of both hands was used as a value of DXR-
BMD for each patient. DXR-BMD values are given in
mg/cm2 per month.
The hand radiographs were sorted on case number
and modality type. Any image that was derived from a
different modality type than other images from the same
patient was removed [11]. Images with severely improper
positioning for DXR-BMD measurements were also
removed.
DXR-BMDwas measured at baseline and after 12 months.
Moderately elevated bone loss was defined as a change in
BMD ≥ 0.25 and < 2.5 mg/cm2 per month and highly
elevated bone loss was defined as a change in BMD
≥ 2.5 mg/cm2 per month (30 mg/ cm2 per 12 month),
defined by the device manufacturer (Sectra, Sweden) [26].
To make the results in this study as usable as possible for
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to other cohorts, a fixed threshold level for highly elevated
hand bone loss (HBL) of the device, that is a DXR-BMD
change ≥ 2.5 mg/cm2 per month, was used for analysis.
Statistical analysis
The distribution of the variables is given as the mean
with standard deviation (SD). The Chi-squared test and
Fisher´s Exact test were used to compare dichotomous
variables between groups and the independent Student’s
t-test, paired-sample T-test and ANOVA to compare
continuous variables between groups (for pairwise com-
parison, Bonferroni test was used). For non-normally
distributed data, and in particular for the radiological
scores, the Mann-Whitney test and Kruskal Wallis test
were used for the comparison between two and three
groups, respectively. Statistical analysis was performed
with SPSS 20 software (SPSS, Chicago, IL, USA).
Results
Baseline characteristics
In the SWEFOT trial, the 487 patients had a total of
1203 hand radiographs performed at the different time
points; of whom 159 patients had radiographs of the
hands, taken within the time-frame of the baseline and
12 months visit ,that qualified for DXR analysis. The
main reason for excluding radiographs was that different
radiographic modalities had been used at baseline and
after 12 months in the same patient. No patient was re-
moved due to severe joint damage or prosthesis since









6.16 (3.20) 6.08 (3.20) 5.86 (3.1
Sex, female 70.6 (344) 72.3 (115) 63.3 (3
ACPA pos.% (n) 63.7 (310) 60.3 (91) 55.6 (2
RF pos.% (n) 68.4 (333) 69.1 (96) 68.2 (3
DAS 28 5.73 (1.01) 5.70 (1.00) 5.23 (0.9
ESR (mm) 39.8 (28.1) 38.6 (26.6) 31.2 (24
CRP (mg/L) 33.7 (42.4) 35.1 (40.4) 27.3 (40
HAQ 1.19 (0.58) 1.19 (0.59) 0.97 (0.4
T-SHS 4.54 (8.01) 4.79 (7.85) 3.04 (6.0
ES 1.91 (3.75) 1.99 (3.56) 1.71 (2.8
DXR-BMD
( g/cm2)
—— 0.58 (0.08) 0.59 (0.0
The values are mean (SD) or percentages (%).
*Between MTX-responders and triple therapy.
** Between MTX-responders and combination MTX + INF.
^ Between triple therapy and combination MTX + INF.
Abbreviation: ACPA: Anti-citrullinated protein antibody, RF: Rheumatoid factor, DAS
CRP: C-reactive protein, HAQ: Health assessment questionnaire disability index, T-SH
ray radiogrammetry, BMD: Bone mineral density.not differ from the whole study population in baseline
characteristics, see Table 1. The number of patients (%)
in the MTX responder, triple therapy and combination
MTX + INF groups was 49 (30.8%), 55 (34.6%) and 55
(34.6%), respectively. There was no difference in the
baseline DAS28 values between the randomized groups
(p = 1.0), but the MTX responders had lower DAS28,
compared with the other two groups (p < 0.05 for com-
parison with those groups combined or each at a time).
The MTX responders group had also a better functional
status (measured by HAQ) than the other two groups
(p < 0.05). Patients with triple therapy had higher ESR
and CRP at baseline, in comparison with the other
groups (p < 0.05). No statistically significant differences
were seen, neither in T-SHS nor in ES between the three
groups at baseline (T-SHS: p = 0.07, ES: p = 0.52). BMD
at baseline did not differ between the groups (p = 0.14).
In the entire study group, there was no difference in
radiographic progression at 24 months between ACPA
positive and ACPA negative patients [change in T-SHS
5.04 (7.42) compared to 4.98 (5.72), p = 0.28]. Neither
was any difference observed between RF positive and
negative patients [change in T-SHS: 7.33 (16.41) com-
pared to 4.23 (6.33), p = 0.50], or between women and
men [change in T-SHS: 5.11 (11.37) vs. 4.03 (5.73), p =
0.65]. Further, patients with radiographic damage at
baseline did not have significantly more progression at
24 months, although a trend was observed [5.87 (12.21)
vs. 3.32 (5.85), p = 0.15]. Patients with T-SHS > 5 at
12 months had more radiographic progression totally





Combination MTX + INF
(N = 55)
p-value
2) 6.00 (3.10) 6.35 (3.40) 0.79
1) 74.5 (41) 78.2 (43) 0.21
5) 62.3 (33) 62.3 (33) 0.74
0) 71.4 (35) 67.4 (31) 0.90
9) 5.99 (1.02) 5.85 (0.92) <0.001*/0.004**/1.0^
.4) 49.3 (27.7) 34.4 (24.3) 0.001*/1.0**/0.008^
.1) 47.1 (41.2) 29.8 (37.7) 0.04*/1.0**/0.07^
7) 1.35 (0.65) 1.25 (0.57) 0.003*/0.04**/1.0^
0) 5.98 (8.53) 5.08 (8.37) 0.07
7) 2.43 (4.32) 1.76 (3.21) 0.52
8) 0.57 (0.06) 0.56 (0.08) 0.14
28: 28 joint-based disease activity score, ESR: Erythrocyte sedimentation rate,
S: Total van der Heijde modified Sharp score, ES: Erosion Score, DXR: Digital X-
Rezaei et al. BMC Musculoskeletal Disorders 2013, 14:79 Page 4 of 9
http://www.biomedcentral.com/1471-2474/14/79p < 0.005 / OR 14.10, 95% CI =5.41–36.73, p < 0.001
(Fisher´s exact test)] and between 12 and 24 months
[1.70 (4.13) vs. 0.62 (1.78), p = 0.03 / OR 9.05, 95% CI =
1.99–40.95, p = 0.001 (Fisher´s exact test)]vs. those who
had T-SHS ≤ 5 points.
Three months follow-up visit
At 3 months follow-up, the mean (SD) DAS28 in the
MTX responder, triple therapy and MTX + INF groups
was 2.41 (0.77), 4.59 (0.96) and 4.86 (1.01), respectively
(p < 0.001, between MTX responders and the randomized
groups). Overall, MTX responders also had lower ESR,
CRP and HAQ, as expected from the trial design. There
were no statistically significant differences in ESR and
CRP between the triple therapy and MTX + INF groups at
3 months follow-up visit (ESR: p = 0.30; CRP: p = 0.28).Clinical characteristics at baseline in patients with and
without radiographic progression and HBL
Table 2 shows the baseline characteristics in patients
with and without radiographic progression, defined as
an increase > 5 units in T-SHS during 24 months, and
similarly in patients with and without HBL during the
first 12 months. Patients with radiographic progression
at 24 months had more inflammatory activity at baseline
than patients who did not progress [higher ESR and
CRP (p < 0.001)]. For patients with or without HBL,
baseline CRP differed significantly (p = 0.004) and a nu-
meric difference was seen for ESR (p = 0.12).
Radiographic progression measured by the van der
heijde modified sharp score (SHS)
The mean (SD) T-SHS at baseline, 12 and 24 months
was 4.79 (7.85), 8.58 (12.72) and 9.76 (13.59), respecti-
vely (p < 0.001). At the same time points the numbersTable 2 Baseline characteristics in the patients with complete
progression or not during the first 24 months (increase in tot
during the first 12 months (DXR-BMD change rate ≥ 2.5 mg/c
Radiological progression
YES (N = 43) NO (N = 101)
Symptom duration, months 6.25 (3.27) 5.98 (3.15)
T-SHS = 0,% 27.9 47.5
ES =0,% 46.5 63.4
DAS 28 5.89 (1.01) 5.60 (1.00)
ESR (mm) 49.8 (30.9) 31.57 (20.9)
CRP (mg/L) 47.7 (41.7) 27.2 (36.2)
RF pos.% 38.3 28.6
ACPA pos.% 64.0 41.4
Abbreviation: T-SHS: Total van der Heijde modified Sharp score, ES: Erosion Score, D
rate, CRP: C-reactive protein, RF: Rheumatoid factor, ACPA: Anti-citrullinated proteinfor ES was 1.91 (3.75), 3.41 (6.10) and 3.70 (6.30),
respectively (p < 0.001). The mean (SD) increase in T-
SHS at 12 and 24 months in the whole group was 3.69
(8.63) and 4.81 (10.11), respectively. There was a nu-
merical but statistically non-significant difference in
radiographic progression over 24 months between the
MTX monotherapy [3.91 (6.72)] and triple therapy [7.40
(14.63)] groups. Patients with triple therapy tended to
have more radiographic progression than patients receiv-
ing MTX + INF [2.72 (4.55)] (p = 0.06). A similar analysis
for increase in ES at 24 months showed a mean (SD) of
1.82 (4.23), 2.42 (6.31), and 0.53 (3.03) in patients with
MTX monotherapy, triple therapy, and MTX + INF
(p = 0.06, between groups) respectively.
Hand bone loss (HBL)
DXR was analyzed in 159 patients and HBL was found
in 23 (MTX monotherapy 2, triple therapy 12 and
MTX-INF 9). The mean (SD) DXR-BMD change in all
patients was −1.06 (1.44) mg/cm2/month, and was non-
significantly lower in the MTX monotherapy group than
in the triple therapy and MTX + INF groups [−0.65
(1.02), −1.22 (1.54) and −1.26 (1.59) mg/cm2/month,
respectively; p = 0.08 between MTX monotherapy and
the randomized groups]. The proportion of patients who
had DXR-BMD change above median (0.71 mg/cm2/
month) was 40.8% in the MTX monotherapy group,
50.0% in triple therapy and 58.2% in the MTX + INF
treated group (p = 0.2). Figure 1 shows the proportion of
patients with normal, elevated and highly elevated DXR-
BMD change in each treatment group. Only 4.1% of
patients in the MTX monotherapy group had HBL dur-
ing the first 12 months, while this was observed in
22.2% and 16.4% of the patients receiving triple therapy
and MTX + INF, respectively (p = 0.01, for MTX mono-
therapy vs. randomized groups).clinical and radiographic data divided by: A) radiological
al SHS score > 5 points) and B) hand bone loss or not
m2/month)
Hand bone loss
p-value YES (N = 23) NO (N = 126) p-value
0.70 5.97 (3.13) 6.70 (3.66) 0.30
0.04 30.5 43.7 0.26
0.04 47.8 59.5 0.36
0.13 5.86 (0.95) 5.66 (0.98) 0.37
<0.001 46.6 (25.9) 37.1 (26.7) 0.12
<0.001 56.9 (47.4) 30.8 (37.6) 0.004
0.30 35.5 30.5 0.68
0.60 56.5 61.4 0.65
AS28: 28 joint-based disease activity score, ESR: Erythrocyte sedimentation
antibody.
Figure 1 The proportion of patients with different amount of hand bone loss (HBL) during the first 12 months in each treatment
group. Only 4.1% of patients with MTX monotherapy had HBL during the first 12 months (p = 0.01, between MTX monotherapy and randomized
groups). The number of patients with HBL in each therapy group: MTX responder: 2/49; Triple therapy: 12/55; MTX + INF: 9/55.
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Patients with HBL had significantly more radiographic
progression over 24 months [10.38 (21.08)] than the
patients without HBL [3.86 (6.42)] as shown in Figure 2
(p = 0.006). Analysis of the ES and JSNS (Figure 2)
showed similar patterns. Radiographic progression be-
tween 12 and 24 months was also statistically significant
in the patients with HBL compared to those without
[2.90 (3.64) vs. 0.88 (3.12) (p = 0.005)]. Figure 3 illus-
trates also well that most of the patients do not have
radiographic progression (30/44 in the monotherapy,
30/53 in triple therapy and 34/47 in MTX + INF group,
respectively). DXR (cut-off > 2.5 mg/cm2/month) had
89% specificity to predict radiographic progression
(T-SHS > 5) but the sensitivity was only 26%.
In the triple therapy group, the mean (SD) increase in
T-SHS was 15.42 (26.65) in patients with, and 5.10 (7.73)
in patients without HBL (p = 0.03). The mean (SD) in-
crease in ES was 5.42 (11.23) and 1.50 (3.73) in patients
with HBL vs. those without HBL, respectively (p = 0.06).
Such differences were not seen in the MTX monother-
apy and MTX + INF treated groups (data not shown).
Patients with HBL had significantly greater risk of
radiographic progression (>5 increase in T-SHS) over
24 months (odds ratio 3.09, 95% CI =1.20–7.79, p =
0.02). This was most marked and only statistically sig-
nificant in the group of patients receiving triple therapy
(odds ratio 4.15, 95% CI = 1.05–16–35, p = 0.04), but not
in the MTX monotherapy group (odds ratio 2.50, 95%CI = 0.14–43.28, p = 0.50) or the MTX + INF group
(odds ratio 1.88, 95% CI = 0.30–11.77, p = 0.50), particu-
larly due to a limited number of patients who had HBL
(n = 2 and 9 in MTX monotherapy and MTX + INF,
respectively).
Treatment changes in patients with and without
radiographic progression or HBL
During the first 12 months of the trial, 19.4% of the
patients changed treatment strategies because of lack of
treatment efficacy or drug side effects. In the triple therapy
group, 32.7% of patients changed treatment over 24 months
(most of them changed to treatment with TNF inhibitors,
data not shown). These patients had more HBL than those
who continued their treatment according to the protocol
[−2.05 vs. −0.81 mg/cm2/month (p = 0.004)], but there was
no difference in radiographic progression between these
two groups (p = 0.95). Eight patients on combination ther-
apy with MTX+ INF discontinued treatment during the
first 12 months, and their radiographic progression or
proportion with HBL did not differ from those who contin-
ued their treatment according to protocol.
Discussion
In this trial based study we present 24 months follow-up
of 159 early RA patients in three different treatment
groups who had radiographic data of the hands correctly
timed and with sufficient quality to be analyzed with DXR.





























Figure 2 Radiographic progression according to the three parameters of SHS (T-SHS: Total van der Heijde modified Sharp score, ES:
Erosion Score and JSNS: joint space narrowing score) during the first 24 months in patients with (black lines) and without (gray lines)
hand bone loss (HBL) during the first 12 months of follow-up.
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24 months as well as between 12 and 24 months. This is
in agreement with previous studies [9,10,13,27]. Less HBL
was observed in patients who had a good clinical response
to MTX after 3 months. Patients who were randomized to
triple therapy had more often HBL than MTX + INF
group, and they also had a greater risk for radiographic
progression if they had HBL. Thus, our findings confirm
and extend previous findings on the predictive value ofHBL measurement for radiographic progression. Stewart
et al. have previously shown in an observational study that
measurement of HBL, using DXR, at 12 months corre-
lated with erosive changes in patients with early RA and
predicted radiographic progression at 48 months follow-
up [27].
Hoff et al. also showed that patients with HBL at
12 months had more radiographic damage at 5 and
10 years in comparison with patients without HBL. In
Figure 3 Radiographic progression (A: total van der Heijde modified Sharp score and B: erosion score) during 24 months in patients
with (n=23) and without (n=121) hand bone loss (HBL). The probalility plot depicts individual radiographic progression for each patient in
ascending order. Radiographic progression is none or minimal for most patients (median: 0), but with a difference in progression between the
groups at the higher end.
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after 12 and 24 months, respectively. Patients with HBL
had higher risk for radiographic damage after 5 and
10 years with an odds ratio (95% CI) of 3.5 (1.42–8.75)
and 3.5 (1.43–8.35), respectively. In our study, the corre-
sponding value is 3.09 (1.20–7.79) after 24 months. In
Hoff´s study, the least significant change (LSC) was
calculated and used as cut-off to define HBL [11].
In the study by Forslind et al. in patients from the
BARFOT study, HBL was defined as a change in DXR-
BMD by more than 0.0048 g/cm2 (4.8 mg/cm2/12 month),
the smallest detectable change (SDC), during the first
12 month. Significant correlation was observed between
HBL during the first 12 months and T-SHS, ES and JSNS
during 24 months. Patients with HBL also had a greaterrisk for radiographic progression with an odds ratio
(95% CI) of 3.0 (1.3–7.4) [9] which is in line with this
study. In another study from “the Lund early RA cohort”,
the same cut-off (4.8 mg/cm2/12 month) was used. In that
study, it was demonstrated that HBL at 12 months was
associated with an elevated Larsen score at year 10 [12].
The main difference between the present and prior
studies is that the fixed threshold levels, recommended
by the device manufacturer (Sectra, Sweden), were used
for analysis, to make the findings as usable as possible
for clinical interpretations as well as for the ability to
compare it with other cohorts. DXR-BMD change rates
were grouped into normal, elevated and highly elevated
bone loss, with threshold levels of 0.25 mg/cm2/month
and 2.5 mg/cm2/month [26] and HBL was defined as
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is higher than the thresholds used in previous studies.
Nevertheless, the findings are similar using different cut-
offs in different studies, indicating that the correlation
between HBL and radiologic progression is not only
dependent on the particular threshold used in each
study cohort.
Good responders to MTX after 3 months were not
randomized in the SWEFOT trial and just continued
MTX as monotherapy. This group had less HBL, but
radiographic damage was more pronounced compared
to the patients who received combination MTX + INF.
In the BeSt study, patients with initial monotherapy had
significantly more HBL than patients on the initial com-
bination therapy [24]. In the PREMIER study, HBL was
also less pronounced in patients with combination ther-
apy and significant differences in HBL and radiographic
progression were seen between combination therapy
(adalimumab +MTX) and MTX monotherapy at 12 and
24 months follow-up [28]. The difference between this
study and those studies is that our patients who had
good clinical response to MTX monotherapy had less
HBL, and a plausible explanation is that our patients
had already demonstrated good clinical response to
MTX as monotherapy whereas in BeSt and PREMIER,
patients were randomized from baseline. However, in
this study, patients in the MTX monotherapy group also
had more radiographic progression according to T-SHS
than patients with combination MTX + INF, confirming
the previously shown positive effect of anti-TNF therapy
on radiographic progression [28].
One limitation of this study was that the radiographs
were not taken for the aim of DXR analysis from the
beginning of the trial. As a consequence, for some
patients, the baseline and 12-month radiographs were not
taken using the same type of instrument and these images
could not be analyzed, but if that would not have been the
case, few images would have had to be excluded from the
study. Thus, if the DXR technology is considered in
advance and the images taken consistently with the same
equipment, there should not be a significant limitation for
DXR in practice. The manufacturer reports a failure rate
below 1/100. Another limitation of our study was the rela-
tively small number of patients (23 patients with HBL at
12 months) which limited the power of the study to
detected small differences and associations. This small
number of patients also resulted in low sensitivity.
Another disadvantage of the current study design was
that the assessment of HBL by DXR was done after
12 months. According to current recommendations,
treatments of early RA should be evaluated earlier [29].
Therefore, future studies should preferably investigate
whether DXR after 3 or 6 months could provide useful
information.However we agree with Forslind et al. [13] that DXR
may have a role in predicting destructive rheumatoid
arthritis in clinical praxis where/when the radiographs
cannot be analyzed according to the scoring systems
used in trials.
Conclusion
In summary, DXR provides information on HBL,
observed in patients with early RA. Non-responders to
MTX had significantly greater risk for HBL than MTX-
responders despite the add-on therapies, and patients
with HBL had significantly greater radiographic damage
after 24 months. Thus, information from DXR may be
complementary to that obtained by clinical assessments
and standard radiography.
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